Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update.

Journal Article (Journal Article)

In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.

Full Text

Published version (via Digital Object Identifier)

Duke Authors

Cited Authors

Salah, HM; Al'Aref, SJ; Khan, MS; Al-Hawwas, M; Vallurupalli, S; Mehta, JL; Mounsey, JP; Greene, SJ; McGuire, DK; Lopes, RD; Fudim, M

Published Date

March 2021

Published In

American Heart Journal

Volume / Issue

233 /

Start / End Page

86 - 91

PubMed ID

33385359

Electronic International Standard Serial Number (EISSN)

1097-6744

International Standard Serial Number (ISSN)

0002-8703

Digital Object Identifier (DOI)

10.1016/j.ahj.2020.12.007

Scholars@Duke